paradigm peptides bpc-157 BPC 157 | Gastric Pentadecapeptide BPC-157: The Body Protection Compound
Description
Understanding this underlying mechanism has guided the development of targeted therapies
(2003) Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes
However, novel advances have led to more stable and orally bioavailable preparations that may augment this peptides already considerable therapeutic potential, especially as it affects the GI tract
LC-MS metabolomics data analysis Data analysis was performed using the Agilent MassHunter Qualitative (v10), Quantitative Analysis and Profinder Software
Bioinformatics (2014) 30(15):211420
